US Congress moderates are now trying to overcome opposition from either end of the political spectrum for a more modest "first step" health care reform bill. And the staffs of Senate Majority leader George Mitchell and moderate Senator John Chafee will spend the next few weeks trying to find some common ground in both new insurance rules to make it harder to deny coverage based on medical histories or other factors, and subsidies for needy families.
Some Democrats feel incremental legislation could kill the momentum for broader change and leave the system worse off, while Republicans are moving back, noting that incremental change could lead to a new entitlement, which some Democrats also fear without any benefits for the poor. Conservatives want some of the money liberals would use for subsidies to be used for deficit reduction.
Representative Newt Gingrich says he could accept the original version of a bipartisan insurance reform bill, but wants guarantees that any legislation would not be expanded significantly in a House/ Senate conference. The American Association of Retired Persons and other groups still hope that a moderate bill can be expanded and are asking people to pressure their Representatives for pro-reform, pro-universal coverage, while yet other groups are opposed to anything other than universal coverage along with systemic reform.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze